Dr. Frédéric Calon is a Professor at the Faculty of Pharmacy and principal investigator at the Centre de recherche du CHU de Québec-Laval University since 2003. He is a biochemist-pharmacist focusing his research program on the development of treatments for neurodegenerative diseases.

Author of more than 120 peer-reviewed articles, he and his team at Laval University, Quebec City, mainly carry on preclinical assays in animal models of brain diseases or neuropathology studies on human brain samples. His fields of expertise are focused on neurodegenerative diseases (Alzheimer’s and Parkinson’s), essential tremor, as well as general neuropharmacology. Dr. Calon is mostly known for his contribution to the discovery of a neuroprotective effect of omega-3 fatty acids in animal models of Alzheimer’s disease, Parkinson’s disease, and ischemic stroke. He cofounded with Sophie Layé (Bordeaux) in 2014 the Laboratoire International Associé (LIA) OptiNutriBrain, a unique collaborative laboratory now one of the world references in research on nutrition and brain diseases.

Dr. Calon’s group has also contributed to the discoveries of neuropathological clues in the cerebellum of patients that had suffered from essential tremor.

Finally, Dr. Calon’s team has developed a unique research platform to quantitatively and qualitatively the capacity of drugs to cross the blood-brain barrier, which is now the limiting step in CNS drug development.

His discoveries have been the subject of hundreds of public reports (radio, TV, and written press) and were highlighted by major national and international media. These discoveries have attracted considerable public interest and media coverage, including prime time interviews for Radio-Canada (TV, radio, internet) and the front page of the Globe and Mail. Dr. Calon’s work on GABA receptors in ET was selected among the top 10 scientific discoveries made in Quebec in 2012 and featured on “Le code Chastenay” on Télé-Québec, and he was also chosen as one of the “Lauréats de Québec LeSoleil/Radio-Canada” (personalities of the week) in 2013. In addition, one of his latest discoveries was published in Paris Match in 2015.

The goal of Dr. Calon’s work is to accelerate the transfer of knowledge from basic neuroscience to clinical applications for CNS diseases.

CHUL
2705, boulevard Laurier
T-2-50
Québec, Québec
Canada G1V 4G2
151 entries « 1 of 16 »

Dufort-Gervais J, Provost C, Charbonneau L, Norris CM, Calon F, Mongrain V, Brouillette J

Neuroligin-1 is altered in the hippocampus of Alzheimer's disease patients and mouse models, and modulates the toxicity of amyloid-beta oligomers.

Journal Article

Sci Rep, 10 (1), pp. 6956, 2020, ISSN: 2045-2322.

Abstract | Links:

Fanet H, Ducrocq F, Tournissac M, Oummadi A, Lo A, Bourrassa P, De Smedt-Peyrusse V, Azzougen B, Capuron L, Laye S, Moussa F, Trifilieff P, Calon F, Vancassel S

Tetrahydrobiopterin administration facilitates amphetamine-induced dopamine release and motivation in mice.

Journal Article

Behav Brain Res, 379 , pp. 112348, 2020, ISSN: 0166-4328.

Abstract | Links:

Bourassa P, Tremblay C, Schneider JA, Bennett DA, Calon F

Brain mural cell loss in the parietal cortex in Alzheimer's disease correlates with cognitive decline and TDP-43 pathology.

Journal Article

Neuropathol Appl Neurobiol, 2020, ISSN: 0305-1846.

Abstract | Links:

Belleville S, LeBlanc AC, Kergoat MJ, Calon F, Gaudreau P, Hebert SS, Hudon C, Leclerc N, Mechawar N, Duchesne S, Gauthier S, Consortium for the Early Identification of Alzheimer's disease-Quebec (CIMA-Q)

The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q).

Journal Article

Alzheimers Dement (Amst), 11 , pp. 787-796, 2019, ISSN: 2352-8729.

Abstract | Links:

Bourassa P, Alata W, Tremblay C, Paris-Robidas S, Calon F

Transferrin Receptor-Mediated Uptake at the Blood-Brain Barrier Is Not Impaired by Alzheimer's Disease Neuropathology.

Journal Article

Mol Pharm, 16 (2), pp. 583-594, 2019, ISSN: 1543-8384.

Abstract | Links:

St-Amour I, Bosoi CR, Pare I, Ignatius Arokia Doss PM, Rangachari M, Hebert SS, Bazin R, Calon F

Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer's disease.

Journal Article

J Neuroinflammation, 16 (1), pp. 3, 2019.

Abstract | Links:

Bourassa P, Tremblay C, Schneider JA, Bennett DA, Calon F

Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer's disease.

Journal Article

Acta Neuropathol, 137 (5), pp. 801-823, 2019, ISSN: 0001-6322.

Abstract | Links:

Tournissac M, Bourassa P, Martinez-Cano RD, Vu TM, Hebert SS, Planel E, Calon F

Repeated cold exposures protect a mouse model of Alzheimer's disease against cold-induced tau phosphorylation.

Journal Article

Mol Metab, 22 , pp. 110-120, 2019, ISSN: 2212-8778.

Abstract | Links:

Laurence M, Benito-Leon J, Calon F

Malassezia and Parkinson's Disease.

Journal Article

Front Neurol, 10 , pp. 758, 2019, ISSN: 1664-2295.

Abstract | Links:

Boutin S, Roy J, Maltais R, Alata W, Calon F, Poirier D

Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10.

Journal Article

Bioorg Med Chem Lett, 28 (22), pp. 3554-3559, 2018, ISSN: 0960-894X.

Abstract | Links:

151 entries « 1 of 16 »
Signaler des ajouts ou des modifications

Active projects

  • Approches clinicopathologiques et précliniques au développement de traitements pour les maladies neurodégénératives, Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers de mérite, from 2018-07-01 to 2022-06-30
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2023-05-01
  • Delivering intrabodies Intracellular antibody delivery using Feldan's proven peptide-based intracellular delivery technology, Partenariat, Consortium québécois sur la découverte du médicament, from 2018-12-01 to 2021-03-31
  • Development of the Feldan Shuttle platform, Partenariat, MITACS Inc., Accélération Québec (MITACS et gouvernement provincial), from 2018-09-01 to 2021-03-13
  • Elimination of senescent endothelial cells to prevent vascular dementia in aging atheroscierotic mice, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2024-09-30
  • Elucidating the role of the Alzheimer risk factor CD2AP in brain capillary endothelial cells and vascular functions, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-10-01 to 2023-03-31
  • How does insulin interact with the blood-brain barrier? Therapeutic implications for diabetes and Alzheimer’s disease, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2020-04-01 to 2025-03-31
  • Institut sur la nutrition et les aliments fonctionnels (INAF), Subvention, Fonds de recherche du Québec - Nature et technologies, Regroupements stratégiques NT, from 2017-04-01 to 2024-03-31
  • Institut sur la nutrition et les aliments fonctionnels, Subvention, Institutionnel - BDR, Instituts reconnus, from 2001-06-01 to 2024-04-30
  • Investigating the contribution of Shank3 in Alzheimer's disease, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2023-03-31
  • Laboratoire international associé (LIA) OptiNutriBrain, Subvention, Institutionnel - BDR, Laboratoire international associé (LIA), from 2015-03-01 to 2025-03-01
  • Manipulating thermogenesis to treat Alzheimer’s disease, Subvention, Société Alzheimer du Canada, from 2019-09-01 to 2021-08-31
  • Mechanisms of endocytosis and transcytosis into endothelial cells of the blood-brain barrier, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2020-04-01 to 2025-03-31
  • Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly diagnosed metastatic pancreatic adenocarcinoma: a feasibility and proof-of-concept study, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2021-09-30
  • Neuronalg - Les effets bénéfiques des macroalgues du Saint-Laurent sur la santé cognitive, Subvention, Ministère de l'Économie et de l'Innovation, (RQM) Odyssée Saint-Laurent du Réseau Québec maritime, from 2020-04-01 to 2022-03-31
  • Nutrition and brain health, from predictive biology to disease prevention and treatment - Food4BrainHealth, Subvention, Institutionnel - BDR, Réseau de recherche international (RRI), from 2019-03-18 to 2024-03-17
  • Nutrition, santé et société (NUTRISS), Subvention, Fonds de recherche du Québec - Santé, Nouveaux Centres et Instituts de recherche - Subventions régulières, from 2019-04-01 to 2024-03-31
  • Phase Two of the Canadian Consortium on Neurodegeneration in Aging, Subvention, Instituts de recherche en santé du Canada, Consortium canadien en neurodégénérescence et vieillissement (CCNV), from 2019-04-01 to 2024-03-31
  • Plateforme Biomarqueurs et cibles thérapeutiques – Cohorte clinique CIMA-Q, Subvention, Fonds de recherche du Québec - Santé, Plateforme de financements de la recherche intersectorielle sur le vieillissement - Living Lab, from 2019-04-01 to 2021-03-31
  • Team 7.1.1: Investigation of cerebrovascular pathology using cerebral microvessel extracts and in animal models, Subvention, Instituts de recherche en santé du Canada, Projet subsidiaire d'un consortium (pour fins de gestion au VRRCI), from 2019-04-01 to 2024-03-31
  • Valorisation d'algues marines et étude de la bioactivité des acides aminés de type mycosporine (NeuronAlg), Subvention, Fonds de recherche du Québec - Nature et technologies, Projet de recherche en équipe, from 2020-04-01 to 2023-03-31

Recently finished projects

  • 3.8 Deciphering host-microbial interactions for cardiometabolic and mental health disorders with novel multimodal light-based sensing tools, Subvention, Secrétariat des programmes interorganismes à l’intention des établissements, Fonds d'excellence en recherche Apogée Canada, from 2016-04-01 to 2020-03-31
  • Clinicopathological Investigations of the substantia nigra in Parkinson's disease, Subvention, Parkinson Canada, Pilot Project Grant, from 2017-07-01 to 2019-06-30
  • Développement de méthodes de détection des acides aminés de type mycosporine dans des extraits d'algues marines et dans des tissus biologiques, Partenariat, Conseil de recherches en sciences naturelles et génie Canada, Subventions d'engagement partenarial pour les universités, from 2018-12-01 to 2019-12-31
  • Understanding the role of thermoregulatory deficits in Alzheimer's disease pathogenesis, Subvention, Fonds de recherche du Québec - Santé, Réseaux thématiques de recherche, from 2018-04-01 to 2019-11-30
Data provided by the Université Laval research projects registery